IDH1 and central nervous system cancer: These results are supported by the findings of Heidenreich et al., who showed in their cohort of 303 gliomas that the patients with only pTERT mutations had worse OS, while the patients with both IDH and pTERT mutations had the best OS (Heidenreich et al. 2015).